Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS study in resectable gastric cancer
NL-OMON50400Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cisplatin and capecitabine in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Started Nov 2006; status: recruiting.
02
Drugs
epirubicincisplatincapecitabine
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON50400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50400.